ReviewSurvey of ophthalmology
Retinal abnormalities in β-thalassemia major.
Review in Survey of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Ocular Complications in Patients With Transfusion-Dependent Beta-Thalassemia Receiving Deferasirox: A Cross-Sectional Study.Health science reports · 2026Article
- Bisretinoid lipofuscin, fundus autofluorescence and retinal disease.Progress in retinal and eye research · 2025Review
- A Case Report of Choroidal Neovascularization Secondary to Angioid Streaks Associated With Beta Thalassemia.Cureus · 2025Article
- Optical coherence tomography findings in patients with transfusion-dependent β-thalassemia.BMC ophthalmology · 2022Article
- Inflammatory adipose activates a nutritional immunity pathway leading to retinal dysfunction.Cell reports · 2022Article
- Macular microvascular changes in children with transfusion-dependent beta-thalassemia.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021Observational
- Novel retinal findings in β-thalassemia major: older age and higher ferritin level as the risk factors.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021Article
- Iron overload and iron chelating agent exposure in anemia-associated outer retinal degeneration: a case report and review of the literature.BMC ophthalmology · 2021Review
- Do We Store Packed Red Blood Cells under "Quasi-Diabetic" Conditions?Biomolecules · 2021Review
- Article
- Long-Term Effects of Iron Chelating Agents on Ocular Function in Patients with Thalassemia Major.Clinical ophthalmology (Auckland, N.Z.) · 2021Article
- Ocular abnormalities in beta thalassemia patients: prevalence, impact, and management strategies.International ophthalmology · 2020Review
- Spectral domain optical coherence tomography findings in Turkish sickle-cell disease and beta thalassemia major patients.Journal of current ophthalmology · 2019Article
- Potential Treatment of Retinal Diseases with Iron Chelators.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Iron promotes oxidative cell death caused by bisretinoids of retina.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Assessing posterior ocular structures in β-thalassemia minor.International ophthalmology · 2018Article
- Electrophysiological assessment for early detection of retinal dysfunction in β-thalassemia major patients.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2017Article
- Evaluation of parafoveal and peripapillary vascular densities using optical coherence tomography angiography in children with thalassemia major.Therapeutic advances in ophthalmologyArticle
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Patients with beta (β)-thalassemia (β-TM: β-thalassemia major, β-TI: β-thalassemia intermedia) have a variety of complications that may affect all organs, including the eye. Ocular abnormalities include retinal pigment epithelial degeneration, angioid streaks, venous tortuosity, night blindness, visual field defects, decreased visual acuity, color vision abnormalities, and acute visual loss. Patients with β-thalassemia major are transfusion dependent and require iron chelation therapy to survive. Retinal degeneration may result from either retinal iron accumulation from transfusion-induced iron overload or retinal toxicity induced by iron chelation therapy. Some who were never treated with iron chelation therapy exhibited retinopathy, and others receiving iron chelation therapy had chelator-induced retinopathy. We will focus on retinal abnormalities present in individuals with β-thalassemia major viewed in light of new findings on the mechanisms and manifestations of retinal iron toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.